Cloxacillin

Summary

Cloxacillin (CHEMBL891) is an approved small-molecule antibacterial agent (ATC J01CF02); indicated across 6 conditions including bacterial infectious disease and staphylococcus aureus infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CF02
• Indications: 6 conditions
• Clinical trials: 6
• Chemistry: 435.9 Da · C19H18ClN3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL891
Name	Cloxacillin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6098
ChEBI	CHEBI:49566
ATC	J01CF02
Molecular formula	C19H18ClN3O5S
Molecular weight	435.9
InChIKey	LQOLIRLGBULYKD-JKIFEVAISA-N

SMILES: CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O

IUPAC name: (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

ChEBI definition: A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.

Pharmacological roles (ChEBI): antibacterial agent, antibacterial drug.

Also known as: Cloxacilina, Cloxacillin, Cloxacilline, Orbenin, cloxacillin, Cloxaciline, CLOXACILLINE, SID174006209, CLOXACILLIN, C0088480, CLOXACILLIN SODIUM

Parent form; salt/anhydrous children: CHEMBL262636, CHEMBL1200388, CHEMBL3989531

Patent coverage: 6,120 distinct patent families (23,927 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Beta-lactamase TEM, Organic anion transporter 3, Bile salt export pump.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
staphylococcus aureus infection	3	MONDO:0005545	EFO:0005681
gram-positive bacterial infections	2	MONDO:0021679	MONDO:0021679
mastitis	2	MONDO:0006849	EFO:1001034
osteomyelitis	0	MONDO:0005246	EFO:0003102

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
Not specified	3
PHASE3	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06726395	PHASE4	RECRUITING	Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia
NCT01792804	PHASE3	COMPLETED	Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
NCT01875263	PHASE3	TERMINATED	Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.
NCT00129688	Not specified	COMPLETED	Once-Daily Amikacin Plus Cloxacillin in Febrile Neutropenic Children
NCT00885300	Not specified	COMPLETED	Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients
NCT03248063	Not specified	COMPLETED	Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).